MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT) from a sell rating to a hold rating in a research note published on Tuesday.

Several other brokerages have also recently weighed in on MXCT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Craig Hallum cut their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.50.

MaxCyte Trading Up 3.9%

MXCT stock opened at $0.70 on Tuesday. The stock has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $1.30. The stock has a market cap of $75.07 million, a PE ratio of -1.63 and a beta of 1.22. MaxCyte has a 1 year low of $0.64 and a 1 year high of $2.96.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $6.76 million for the quarter, compared to analyst estimates of $9.16 million. MaxCyte had a negative return on equity of 22.15% and a negative net margin of 135.14%. On average, analysts forecast that MaxCyte will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Large investors have recently made changes to their positions in the stock. Prudential Financial Inc. bought a new position in shares of MaxCyte in the second quarter valued at $26,000. State of Wyoming bought a new stake in MaxCyte during the second quarter worth $38,000. Kwmg LLC lifted its stake in MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after acquiring an additional 11,135 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after acquiring an additional 18,913 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new position in shares of MaxCyte in the 2nd quarter valued at about $60,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.